What is the drug thought to do in the body?
In about 97% of people with MND, a protein called TDP-43 becomes faulty and forms abnormal clumps, which contributes to motor neuron damage. One characteristic of faulty TDP-43 is the addition of small extra molecules, which could change the behaviour of the protein. Tideglusib is thought to stop the addition of these extra molecules. In cells from people with MND, as well as in a mice who have faulty TDP-43, Tideglusib was shown to reduce the amount of TDP-43 with extra molecules.
Phase 2 - TIDALS
Current status: Not yet recruiting
Primary objective: To test safety and tolerability of Tideglusib in people with MND
Tideglusib has already been through clinical trials for several other conditions, and is known to be safe. This means that a phase 1 trial was not needed. The main aim of the phase 2 trial is to see whether Tideglusib is well tolerated in people with MND. The trial will also look at side effects of the drug, and the effect of the drug on clinical measures including the ALSFRS-R scale. People who take part in the trial will be randomly assigned to take either Tideglusib or a placebo (dummy drug) for 14 weeks. You can find out more about the trial here.
The trial is recruiting in Switzerland.
Last updated: 05/06/25